Novo Nordisk's Q1 2026 print clarified the contribution ↗ of Wegovy ↗ HD (semaglutide ↗ 7.2 mg injection), the high-dose semaglutide formulation approved by the FDA in March and launched in the US on April 7. The STEP UP trial that supported the approval showed 21% mean weight loss at 72 weeks for patients who stayed on treatment (19% all-patients), with 89% achieving at least 5% body-weight reduction versus 38% on placebo. The label requires four-plus weeks of tolerability on the standard 2.4 mg dose before stepping up. NovoCare lists the 7.2 mg self-pay price at $399 per month, with insured patients paying as little as $25 via the savings offer. The dysesthesia signal at 22% (versus 6% on 2.4 mg and 0.3% on placebo) is the safety chapter that prescribers and patients will need to engage explicitly.
The efficacy in context. 21% mean weight loss at 72 weeks puts Wegovy HD on par with the higher end of the obesity-drug class. Tirzepatide ↗'s pivotal SURMOUNT trials showed mean weight loss in the low-twenties at 72 weeks. Retatrutide ↗'s TRIUMPH-4 in obesity-with-knee-osteoarthritis showed 28.7% ↗, but that is a different patient population. Wegovy HD is the first higher-dose semaglutide formulation, and the 21% number suggests the dose-response curve still has room above the 15% range that the standard 2.4 mg dose typically delivers in similar trials.
The safety chapter. Dysesthesia, defined clinically as abnormal sensation typically presenting as tingling, burning, or itching, occurred in 22% of patients on Wegovy HD versus 6% on the standard 2.4 mg dose and 0.3% on placebo. The four-fold higher rate compared with the standard dose is the only meaningful safety signal beyond the broader GLP-1 class adverse-event profile. Clinical mechanism is unclear. The implication for prescribing is straightforward: patients escalating to the high dose need to be counseled on the dysesthesia risk, which is uncommon at lower doses but common enough at 7.2 mg that one in five patients will encounter it.
The label-required step-up. Patients must demonstrate at least four weeks of tolerability on semaglutide 2.4 mg before being eligible for the 7.2 mg dose. The structural reason is to filter out patients who cannot tolerate the lower-dose effect profile (gastrointestinal events being the dominant mode) before exposing them to the higher-dose effect profile. Operationally, this means Wegovy HD is a step-up product for patients already established on Wegovy 2.4 mg rather than a starting dose. The premium tier is positioned as the upgrade path within the franchise, not as the entry point.
Why this matters commercially. Wegovy HD differentiates Novo's obesity pipeline at the higher-efficacy end of the class. The 21% weight loss number is competitive with tirzepatide pivotal data on a comparable timeframe; the once-weekly injectable schedule and the established Wegovy brand recognition support transition rather than substitution. For patients who have plateaued on standard-dose Wegovy 2.4 mg, the HD upgrade path keeps them in the Novo franchise rather than driving them to switch to Mounjaro ↗/Zepbound ↗. The launch positions Novo to defend its share against Lilly's upcoming retatrutide submission (late 2026 or 2027) without needing a new molecule.
The platform read. The GLP-1R ↗ target page on peptidemodel hosts the GLP-1(7-36) amide ↗ card that anchors the platform's reference for the semaglutide pharmacology. Wegovy HD is the same molecule at a higher dose, which highlights the dose-response question the platform's design space already cares about: at what point does receptor saturation kick in, and what is the optimal dose-response curve for receptor-binding peptides in chronic-dose obesity therapy. The 21% efficacy at 7.2 mg with 22% dysesthesia is one data point on that curve.
What the launch trajectory has to show. Three questions over the next two quarters. First, how many patients on standard 2.4 mg actually escalate to 7.2 mg, given the dysesthesia rate and the savings-offer-versus-self-pay tier structure. Second, whether the 21% efficacy in trial translates to comparable real-world outcomes when patients move up the dose ladder more selectively. Third, whether a second higher-dose product (semaglutide 9 mg or beyond) is in the Novo pipeline, given that the dose-response curve apparently has not flattened by 7.2 mg. Each is testable by Q4 IQVIA data and Novo's Q3 commentary.